{"id":"W2160719528","doi":"10.1200/jco.2009.24.0143","title":"Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Clinical Oncology Group; University of Toronto; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Cyclophosphamide; Internal medicine; Metastatic breast cancer; Prednisone; Vascular endothelial growth factor; Chemotherapy; Gastroenterology; Clinical endpoint; Breast cancer; Phases of clinical research; Oncology; Progressive disease; Methotrexate; Cancer; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002968939,0.0004429122,0.003023461,0.0003125923,0.0001153399,0.00002016328,0.0001761109,0.0003330754,0.00031391],"category_scores_gemma":[0.00104464,0.0003140319,0.0005817726,0.0001934242,0.0005601697,0.0002820494,0.00004178569,0.0005179028,3.000337e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002293669,"about_ca_system_score_gemma":0.002471365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004324326,"about_ca_topic_score_gemma":0.00002081296,"domain_scores_codex":[0.9953381,0.001109919,0.00216762,0.0005139193,0.0004371432,0.0004332839],"domain_scores_gemma":[0.9921198,0.004246203,0.00236337,0.00022197,0.0005405635,0.0005081057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7682071,0.00719636,0.006370854,0.0001062229,0.006018931,0.00004690453,0.0006844358,0.000004385678,0.1335539,0.00001911917,0.0001840156,0.07760774],"study_design_scores_gemma":[0.6107607,0.2536356,0.09459596,0.0002052459,0.003551867,0.0003504487,0.0002288768,0.0001389072,0.02949889,0.0003898758,0.006208176,0.0004354336],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916575,0.003016535,0.0003069877,0.002183172,0.0006311067,0.001735969,0.0004321196,0.00001079516,0.00002579002],"genre_scores_gemma":[0.9740726,0.01321267,0.0109578,0.0008591062,0.0006675549,0.0000325313,0.000006845948,0.00006035999,0.0001304962],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2464392,"threshold_uncertainty_score":0.9999312,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08840411151474677,"score_gpt":0.4399860116120404,"score_spread":0.3515819000972936,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}